The activity of the peptides has been evaluated in tumors formed by the FC1199 tumor cells, derived from KPC mice, the model used to first demonstrate the activity of the CCN2 inhibitor FG-3019 in PDAC. The gene discussed is CCN2; the disease is neoplasm.